CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Acadia Healthcare Q3 revenue beats estimates; 2026 outlook raised

By Reuters News


Overview

  • US behavioral health provider's Q3 revenue rose 5%, beating analyst expectations

  • Q3 adjusted EBITDA beat analyst expectations

  • Company raised full-year 2026 revenue, adjusted EBITDA, and adjusted EPS guidance


Outlook

  • Acadia raises 2026 revenue guidance to $3.44-$3.46 bln from $3.40-$3.45 bln

  • Company lifts 2026 adjusted EBITDA outlook to $615-$625 mln from $590-$615 mln

  • Acadia increases 2026 adjusted EPS forecast to $1.70-$1.80 from $1.45-$1.60


Result Drivers

  • ACUTE INPATIENT GROWTH - Acute inpatient psychiatric facility revenue rose 11% as patient volumes increased 7.5%, driven by expanded capacity at new and existing facilities

  • SPECIALTY FACILITY DECLINES - Specialty treatment facility revenue fell 8% due to declines in Pennsylvania and closures of several facilities over the past year

  • HIGHER OPERATING EXPENSES - Total operating expenses rose 6.4%, with salaries, wages and benefits up 6.1% due to new facility openings and routine wage increases


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$895.31 mln

$877.79 mln (12 Analysts)

Q3 Net Income

$38.65 mln

Q3 Adjusted EBITDA

Beat

$176.40 mln

$161.10 mln (13 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Acadia Healthcare Company, Inc. is $32.50, about 9.7% above its November 3 closing price of $29.62

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 17 three months ago


Reuters Recommended Reads

  • Nov 4 - Health insurers, hospitals rally after sweeping midterm win for Democrats

  • Nov 3 - Senior care provider InnovAge's Q1 revenue beats as participants increase

  • Nov 3 - Addus HomeCare Q3 adjusted EPS beats estimates; to acquire AccentCare personal care division


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.